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Abstract
Objective—Left ventricular hypertrophy (LVH) is a highly prevalent and robust predictor of
cardiovascular morbidity and mortality. Existing studies have finely detailed mechanisms involved
with its development, yet clinical translation of these findings remains unsatisfactory. We propose
an alternative strategy focusing on mechanisms of LVH regression rather than its progression and
hypothesize that LVH regression is associated with a distinct genomic profile
Methods—Minimally-invasive transverse arch banding and debanding (or their respective sham
procedures) were performed in C57Bl6 male mice. LVH was assessed physiologically by
transthoracic echocardiography, structurally by histology, and molecularly by real-time PCR.
Mouse hearts were genomically analyzed with Agilent mouse 44k developmental gene chips.
Results—Compared to controls, animals banded for 28 days developed a robust hypertrophic
response by heart weight/body weight ratio, histology, echocardiography, and fetal gene
expression. These parameters were reversed within 1 week of debanding. Whole genome arrays on
LV tissue revealed 288 genes differentially expressed during progression, 265 genes differentially
expressed with regression, and only 23 genes shared by both processes. Signaling-related
expression patterns were more prevalent with regression rather than the structural-related patterns
associated with LVH progression. In addition, regressed hearts showed comparatively more
changes in energy metabolism and protein production.
Conclusions—This study demonstrates an effective model for characterizing LVH and reveals
that regression is genomically distinct from its development. Further examination of these
expression profiles will broaden our understanding of LVH and provide a novel therapeutic
paradigm focused on promoting regression of LVH, not just halting its progression.
Left ventricular hypertrophy (LVH) affects approximately 25% of adult Americans and is
most often associated with pressure overload as seen with essential hypertension, aortic
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stenosis and ischemic heart disease.1 LVH is highly morbid and is a robust risk factor for
cardiovascular mortality.2 Yet, despite optimal blood pressure control, treated hypertensive
patients rarely achieve more than a 15–20% reduction in LV mass. Furthermore, nearly half
of these patients will continue to have LVH progression and increased cardiovascular
events, including death.3 Thus, there remains a great need to expand our understanding and
treatment of LVH.
To date, most experimental and therapeutic approaches addressing pressure-induced LVH
have been directed at its progression. Numerous studies have profiled the genomic response
to aortic banding at multiple time points,4 in different chambers,5 and in different genders.6
Collectively, these types of studies have exquisitely detailed and identified mechanistic
targets that may be blocked to delay or retard LVH progression,7, 8 but have not been
effective in advancing therapy for existing disease. As opposed to the plethora of studies
focusing on LVH development, few studies have attempted to characterize independent
features of LVH regression. Friddle and colleagues first detailed genomic differences with
LVH regression using nascent gene array technology following administration and
withdrawal from beta-adrenergic agonists.9 Although no significant physiologic differences
between groups were discerned, 8 genes unique to the drug removal were identified. Despite
only 4,000 genes on the array platform, this study revealed that gene expression differences
between groups may exist in the absence of detectable physiologic changes, and that array
technology might be sensitive enough to highlight these differences.
We and others have demonstrated that removal of a previously placed constrictive aortic
band can allow reversal of LVH.10, 11, 12 Similarly, studies of human patients with LVH that
have aortic valve replacement for aortic stenosis are highly successful in causing LVH
regression.13 It remains unknown, however, if LVH regression is truly a unique process and
thus a target for focused study and intervention. Accordingly, we sought to determine if
gene expression associated with physiologic LVH regression was not simply the reverse of
those genes associated with LVH progression, but rather a distinct genomic pattern.
MATERIALS AND METHODS
Surgical Model and Experimental Design
In accordance with both an institutionally approved IACUC protocol and NIH guidelines,
10-week-old C57Bl6 male mice were randomly assigned to one of 4 groups: Sham (S), Band
(B), Sham Deband (SDB), and Deband (DB). The 60 mice enrolled were partitioned as
follows: 10 S, 15 B, SDB 13, and DB 21. Mice in the Sham and Band groups underwent
minimally invasive transverse aortic banding as previously described.10 Briefly, animals
were anesthetized using inhaled isoflurane by facemask. A midline neck incision was used
to approach the anterior mediastinum. The transverse arch was identified and a constrictive
band was placed and tightened to the approximate diameter of a 27 gauge needle. The only
difference between sham and band groups was that in the sham animals, the constrictive
band was not tightened. Adequate placement of the band was verified by evaluation of
carotid Dopplers both before and after placement of the aortic band. Adequate banding was
accepted when the Doppler velocity ratio doubled from right to left carotid arteries. Animals
in the Deband and Sham Deband had initial procedures identical to those for the Band and
Sham animals, respectively. At 4 weeks, the aortic band was removed, heretofore referred to
as debanded.10 Efficiency of debanding was verified by carotid Doppler with normalization
of carotid velocities. Deband and Sham Deband animals were sacrificed one week following
the deband procedure for all evaluations except histology, where animals were sacrificed
both at 1 and 4 weeks after debanding.
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Transthoracic echocardiography was performed using the Vevo 660 High Resolution
Biomicroscopy System equipped with a 30 Mhz transducer (Visual Sonics, Toronto, CA).
During examination, mice were anesthetized with 1–1.5% inhaled isoflurane. Depth of
anesthesia was standardized by recording images at heart rates of 480–520 bpm. Images
were recorded in all animals before surgery, at 2 and 4 weeks after banding, and at 1, 2, 3,
and 4 weeks after removal of aortic constriction (debanding). Two technicians, blinded to
the animals’ experimental status, performed exams and measurements.
Tissue Procurement
At time of sacrifice, hearts were rapidly excised and the left ventricular apices were
sectioned and flash frozen in liquid nitrogen for gene array analysis. Additional animals
allocated to histological analysis were perfused with PBS followed by 10% Formalin, fixed
overnight in Formalin, and then processed for histological analysis using periodic acid
Schiff staining.14 Cardiomyocyte cross-sectional area was measured using ImageJ (v.
1.38j).15
RNA Preparation, MicroArray Process, and Real-Time PCR
To minimize variation between mice within a tested group and to enhance detection of
variation between experimental groups, semi-pooled groups of mice were created. For each
experimental group, 9 mice were selected from a group of up to 22 based on
echocardiographic criteria of both progression with banding (increase in LVmass of >20%)
and regression with debanding (decrease in LVmass of >10%). Within these groups,
subgroups of 3 animals were randomly pooled so that 3 samples would be created for each
experimental group.
LV apices were homogenized in 0.5ml of ice cold Trizol solution (Sigma) using a bead mill
homogenizer (Retsch, Newtown, PA). RNA was then isolated using the standard trizol
procedure with additional steps for removal of DNA and fibrous tissue. Purity of RNA was
verified by using a 260/280 ratio ≥1.95. An Agilent BioAnalyzer 2100 instrument was used
to verify RNA integrity for all samples. 500 ng of total RNA was labeled with Cyanine-5
CTP in a T-7 transcription reaction using the Agilent Low Input Linear RNA Amplification/
Labeling System. Labeled cRNA from samples was then hybridized to Agilent mouse 44k
developmental microarray slides in the presence of equimolar concentrations of Cyanine-3
CTP labeled mouse reference RNA prepared from pools of 1-day-old mouse pups. Real-time
PCR was performed using Taqman primers and probes (Applied Biosystems International
(ABI), Foster City, CA).
Western blot
Protein fractions were isolated in ice cold lysis buffer during dounce homogenization.
Concentrations were determined using the Bradford assay. Protein fractions were denatured
in loading buffer. 30 μg of each sample was then loaded into alternating lanes for gel
electrophoresis. Membrane transfer was performed overnight and rabbit anti-mouse
antibody was used to probe for Plk1 and Hpcal1. GAPDH was used as the loading control.
Statistical Methods
All physiologic data are presented as mean ± standard error (SE) except where noted. Real-
time PCR data were log transformed prior to comparison. All comparisons of physiologic
data were performed using 2-tailed, type 3 or type 1 t-tests. Microarray data (N=12 arrays)
were Loess normalized and probes were filtered for features having a normalized intensity
of <30 aFU in either red or green channels. Probes were removed if data was not present in
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at least 9 of 12 samples. Missing data points were imputed (to facilitate further statistical
comparisons) using the k nearest neighbors algorithm (k=2). Samples were then
standardized (μ=0, σ=1) using a custom Perl script (ActiveState Perl 5.8.1, build 807,
release date 2003-11-6). Differences in expressed genes were validated using significance
analysis of microarrays (SAM) with a false discovery rate of 5%.
Linear models for microarray (Limma)16 was used to model the variation in all data sets,
and perform the following contrasts: Band vs. Sham, Deband vs. Sham Deband, and
(Deband –Sham Deband) vs. (Band – Sham). These contrasts were executed using custom
scripts written in the R statistical language and environment (“R”; Version 2.2.1, build
r36812, release date 2005-12-20). Genes were identified as significant in each contrast with
the criteria P ≤0.01 and mean fold change ≥ 1.2.
Unsupervised gene and array clustering was performed for each comparison: Band vs.
Sham, Deband vs. Band, and Deband vs. Sham Deband. Data for each gene being compared
were filtered for 3 instances of mean fold change ≥2. Data were further adjusted by median
centering the genes. Average linkage hierarchical clustering using centered correlation
similarity metric for both genes and arrays was performed using Gene Cluster 3.0 (Michiel
de Hoon, University of Tokyo, Human Genome Center, 2006). Data were then visualized
using Java TreeView (version 1.0.13).
Gene ontologies of significant genes in each contrast were identified using the NIH curated
DAVID (Database for Annotation, Visualization, and Integrated Discovery) 2007.17 To
facilitate interpretation of gene ontology, functional clustering was performed and results
were rank ordered by DAVID using enrichment analysis, and were further organized
according to the number of genes in that cluster relative to the total number of genes
identified within a particular contrast. The primary advantage of the DAVID technique is its
ability to take large lists of genes and identify the biological processes and functions that are
most important (within the set of significant genes) to the biological phenomenon under
study. Orthogonal filtering of data sets was performed using the Significance Analysis of
Functional Expression (SAFE)18 using custom R scripts. In this method, also called
orthogonal filtering, all genes are first organized based on their gene ontologies, or GO
categories. Each ontologic category is then evaluated based on the degree of variation of
individual genes within that category, regardless of the significance of individual genes. The
more randomly the genes within each ontology are distributed, the less likely that that
ontology is contributing to the observed differences in the experimental groups. Ontologies
are then ranked based on their relative significance to the process under study. Essentially,
the entire gene array is used to generate meaningful information about the process under
study, rather than just a few dozen genes that are identified as significantly different. Gene
ontologies with a P-value of 0.1 or less were identified in all contrasts.
RESULTS AND DISCUSSION
Regression of pressure-induced LVH
Sixty mice were used in this study: 2 died perioperatively and 2 were excluded with wound
infections. Our technique of minimally-invasive banding and debanding effectively
produced LVH with subsequent regression. Doppler velocity ratios between right and left
carotid arteries verified creation and relief of arch obstruction as previously demonstrated.10
Grossly, heart-weight to body-weight ratios similarly increased with banding and
normalized after debanding (Figure 1A). Echocardiographically, aortic constriction resulted
in increased wall thickness, greater chamber dimensions, and significantly greater LV mass
(Figure 1A, Supplementary Data, Table 1). One week following band removal, most
parameters changed in the direction of baseline, with a favorable trend noted in fractional
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shortening. Histologically, cardiomyocyte cross sectional areas increased approximately
20% following banding, and declined significantly following debanding (Figure 1B, C). To
determine the corresponding molecular changes, three common genetic expression markers
of ventricular hypertrophy were evaluated using real-time PCR, including beta myosin
heavy chain, natriuretic peptide type B, and skeletal muscle α1-actin (n=6–8). All were
significantly upregulated in the banded animals and normalized in debanded mice. For
example, natriuretic peptide levels increased 65.4 ± 25.4 fold with banding (sham 1.0 ± 0.2
fold, p<0.05) and decreased with debanding (2.9 ± 0.8, versus banding p<0.05). Taken
together, these data comprehensibly demonstrate a reproducible model to study mechanisms
independently associated with LVH regression.
Identification and clustering of significant genes
In order to minimize variation in for our array experiments, we used echocardiography to
select 9 animals from a larger starting cohort of mice for each group (n=11–22). The
sensitivity of the array technology demanded that we study the best representative animals
for each group. Furthermore, at the time of these studies, it was cost prohibitive to do
individual arrays for each animal. Nevertheless, changes in LV mass index were not
significantly different between the full and array data sets. i.e. %Δ Band (total, n=17) 35.2 ±
4.3 compared to Band (array, n=9) 42.6 ± 5.0, p=0.29 and the %Δ Deband (total, n=22) −9.8
± 1.9 compared to Deband (array, n=9) −15.1 ± 1.6, p=0.09. After preliminary filtering and
standardization, a total of 14,693 distinct transcripts were identified in our heart tissue and
analyzed using linear models for microarray (Limma). In the regression contrast (Deband vs.
Band), we identified 255 differentially expressed genes: 92 were upregulated, and 133 were
downregulated. Contrasts for LVH progression (Band vs. Sham) and for the regressed state
(Deband vs. Sham Deband) identified 288 and 727 differentially expressed genes
respectively (Figure 2A). During LVH progression, there were 158 upregulated and 130
downregulated genes, and in the Deband vs. Sham Deband contrast there were 244
upregulated and 483 downregulated (detailed profiles for each contrast provided in
Supplemental Data, Table 2).
Interestingly, we identified only 23 genes that were significantly differentially expressed in
both LVH progression and regression. Conversely, 108 genes were distinctly associated with
regression. In examining the most differentially upregulated genes in regression, there were
2 cell cycle control genes, polo-like kinase 1 (Plk1) and midkine (Mdk), a myosin peptide
not previously associated with the heart (Myh1), the neural conduction protein Hpcal1, and
Pramef12, a protein with homology to a melanoma associated protein (Figure 2B). Of these,
only midkine has previously been associated with cardiovascular disease.19 Western blot
analysis confirmed the relationship between our gene array and protein expression for Plk1
and Hpcal 1 (Figure 2C). Among the most downregulated genes in regression, only the
trends in Nppa expression were consistent with our prior understanding of LVH, and
changes in expression of the remaining genes were unique to this experiment.
Although we identified changes in expression of individual genes, we sought to determine if
LVH regression was associated with a distinct genomic pattern. Indeed, unsupervised
clustering of the samples in each comparison showed clear separation of Band and Sham
groups, and of the Deband and Band groups (Figure 2D). The separation was less distinct in
the Deband vs. Sham Deband comparison, with one sample from Deband and one sample
from Sham Deband not clustering appropriately. This observation indicates that the
expression patterns of the Deband and Sham Deband groups were less significant than might
otherwise have been predicted based on individual gene differences originally identified by
Limma. Taken together, the global expression pattern depicted in the unsupervised
clustering suggests that differences between groups were not limited to a few hundred genes,
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but rather several thousand, and those differences were consistent from one group of animals
to another.
Gene expression profiles associated with LVH regression
In the LVH progression analysis, gene ontology clustering of our most significant genes
showed expected characteristics of hypertrophic stress, including a large focus on actin,
microtubules, cytoskeletal integrity, and contractile function, with the remainder including
organelle production, transport, and organization (Table 1; Supplementary data, Figure 1).
Similarly designed gene array studies of LVH progression (in mice) have identified these
same genomic themes.5 In the regression analysis, none of these cytoskeletal or contractile
clusters were differentially expressed. Instead, there was a predominance of intra- and extra-
cellular signaling themes. Further breakdown of the functional clusters involved in the
regression process indicated that cell growth, morphogenesis, and cell cycle were all highly
upregulated, while metabolism, and protein and nucleotide production, were downregulated.
Lastly, the regressed state (DB vs. SDB) had 126 overlapping genes that demonstrated
mostly activity in metabolism and in mitochondria and other organelles. This is markedly
different from the patterns associated with either LVH progression or regression. This latter
observation suggests that although the debanded hearts appear structurally similar to sham-
debanded hearts, they remain genomically distinct.
We next evaluated all 14,693 expressed genes using the orthogonal filtering methodology
SAFE in order to identify significant gene ontologies and gene set enrichment analysis
(GSEA) categories that were relevant to the processes of both LVH progression and LVH
regression. The SAFE analysis is particularly useful as it gathers information from all genes
in the experiment, not merely ontologies characterized by statistically significant genes. In
regression, there were 52 gene ontologies and 34 GSEA categories with p≤0.1
(Supplementary Data, Table 3). Importantly, only 5 gene ontologies were identified as
common to both LVH progression and regression (Supplementary Data, Table 4). These
data further distinguish LVH regression as an independent process. Taken together, the
DAVID and SAFE ontologic analysis corroborate differences identified at the individual
gene level and demonstrate that LVH regression is associated with a distinct thematic
pattern of gene expression.
Commentary
Our results compare favorably to a recently published study that detailed gene expression by
microarray in rats following transverse arch debanding.12 Although they identified 52
regression-related genes, animals that received an operation 2 weeks prior to heart
procurement were compared to animals 24 hours after reoperative chest surgery to remove
an inflammatory silk band. Thus, many transcripts might actually reflect differences
attributed to the perioperative systemic inflammatory response. We purposefully and
rigorously designed (cage strategy, circadian cycling of procedures) our study, in a
minimally-invasive murine model, to avoid confounding perioperative variables.
Furthermore, no quantifiable physiologic data is reported to indicate that LVH regression
actually occurred. Additionally, statistical issues evaluating fold-changes between groups
(differences are expressed in relation to a single sham control group, not between the
contrasting groups) are magnified when the essential comparison only utilized 3 animals, as
opposed to 9 animals in each of our groups. Finally, their study utilized a limited array
platform with less than 10,000 transcripts, possibly limiting their scope of observation,
especially when compared to the whole genome platform used in our present study.
Hypertrophy and atrophy have similarly been studied in skeletal muscle, and the processes
have much in common with the progression and regression of LVH. For example, atrophy
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has been previously demonstrated to be an active process with a distinct pattern of gene
expression, rather than simply the genomic reverse of muscle hypertrophy.20, 21 Functional
genes associated with atrophy and regression involve increased protein degradation,
downregulation of ATP production, decreased glycolysis, a decrease in growth protein
synthesis, and altered ECM production – all categories that we identified in regression
compared to LVH. Fundamentally, however, muscle atrophy typically describes progression
to a disease state, while regression of LVH is a return to a normal physiologic state. In this
regard, and because of the intrinsic physiologic differences between skeletal and cardiac
muscle, we believe that mechanistic inferences must be limited in all but the final pathways
that directly result in decreased muscle mass.
Our results must be viewed with several caveats. In this study, we have examined in detail
the effects of banding at only 1 timepoint (4 weeks) and for only a discreet period of
pressure unloading (1 week). We suspect that the influence of pressure-relief when the
ventricle is either less (2–3 weeks of banding) or more stressed (6 weeks or more of
banding) would offer different structural and genomic patterns. We thus are likely
witnessing a continuum of change as the heart both negatively and positively remodels. We
chose to organize the array around the 1 week timepoint because our preliminary data
indicated that the effective physiologic and structural reversal of LVH was nearly complete
at this time (and far-enough away from the surgical procedure), despite differences in gene
expression. As demonstrated simply in the Venn diagram, structural reversal did not create a
“normal heart” as assessed genomically. These observations will propel more detailed
studies focusing on timing and better understanding of the reversed state. Finally, we
acknowledge that this model is really a model that relieves acute pressure overload
(banding). Thus, parallels to the insidious pressure-overload that occurs with typical aortic
stenosis in human, and its subsequent reversal with aortic valve replacement,13, 22 can only
be inferred.
In conclusion, we demonstrate that relief of pressure overload-induced LVH is not simply
the reverse of LVH progression, but rather a unique process with a specific gene expression
profile. Therapeutic approaches to LVH based on enhancing regression, rather than
impeding progression, are rarely pursued. Elaborating mechanisms associated with both
regression and the regressed state have great potential for identifying novel and clinically
relevant strategies for treating patients with LVH.
Clinical Implications
Much attention is given to the study of mechanisms involved with the development of LVH
and heart failure. Unfortunately, current strategies have not markedly altered the natural
history of this disease. Aortic valve replacement for severe aortic stenosis (ie: removing the
band) has clearly demonstrated a favorable impact in cardiac remodeling. Yet, there is a
large subset of patients with LVH from pressure-overload that do not regress and have
increased risk of cardiovascular morbidity and mortality. While an allure exists to jump to
elaborate therapies for HF (for example, cellular replacement and stem cell injections), a
great need exists to identify underlying mechanisms associated with myocardial recovery
that can subsequently be targeted for sole therapy or perhaps in combination with
mechanical unloading (AVR or ventricular assist). While LVH experimentation in mice is
temporally quite different from humans, it is none-the-less an important first step in
characterizing the genomic signature associated with cardiac remodeling, and will enhance
future work in myocardial recovery therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Physiologic and structural evidence of LVH reversal. (A) Heart weight/body weight ratios
(n=11–22 per group) and serial echocardiographic measurements showing changes over
depicted time period (n=11–22 per group) (abbreviations in Supplement). (B) Left ventricle
cross-sections stained with PAS. (C) Calculated cardiomyocyte cross-sectional areas (n=4
per group). *p<0.05 vs. Sham, †p<0.05 vs. Band.
Stansfield et al. Page 10














Gene expression associated with LVH regression. (A) Venn diagram depicts different and
shared genes in each experimental contrast (p<0.01 and absolute fold change >1.2). (B)
Most differentially expressed genes in the regression contrast (Deband versus Band). (C)
Western Blot for selected proteins identified in the Deband vs. Band comparison. (D)
Unsupervised gene clustering between groups (B, band; S, sham; DB, deband; SDB, sham-
deband).
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Table 1
Gene ontology clustering of significant genes between respective groups as assessed by DAVID 2007 and
listed in order of prevalence.
Band vs Sham Deband vs Band Deband vs Sham Deband
Organelle Production Protein glycosylation Cellular metabolism
Intracellular transport Extracellular signaling Protein metabolism
Actin/cytoskeletal organization Glycosaminoglycan binding Organelle organization
Contractile protein binding Cell adhesion Intracellular transport
Nucleotide binding Cell cycle control Ion binding
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